These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 29367723)
41. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118 [TBL] [Abstract][Full Text] [Related]
42. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Krammer F Biotechnol J; 2015 May; 10(5):690-701. PubMed ID: 25728134 [TBL] [Abstract][Full Text] [Related]
43. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses. Bolduc M; Baz M; Laliberté-Gagné MÈ; Carignan D; Garneau C; Russel A; Boivin G; Savard P; Leclerc D Nanomedicine; 2018 Nov; 14(8):2563-2574. PubMed ID: 30193813 [TBL] [Abstract][Full Text] [Related]
45. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315 [TBL] [Abstract][Full Text] [Related]
51. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles. Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508 [TBL] [Abstract][Full Text] [Related]
56. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins. Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240 [TBL] [Abstract][Full Text] [Related]
57. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice. van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H Front Immunol; 2018; 9():2350. PubMed ID: 30369928 [TBL] [Abstract][Full Text] [Related]
58. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Cho A; Wrammert J Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684 [TBL] [Abstract][Full Text] [Related]
59. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses. Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350 [TBL] [Abstract][Full Text] [Related]
60. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]